- $106.64m
- $100.07m
Brief: Polypid Regains Compliance With Nasdaq Minimum Closing Bid Price Rule
Brief: PolyPid Says Top-Line Results Of Phase 3 Shield II Trial Of D-PLEX(100) Expected In Mid-2024
Brief: Polypid Announces Publication Of Preclinical Data Further Supporting The Good Safety Profile Of D-Plex₁₀₀ And Plex Technology Platform
Brief: Polypid Announces Successful Commercial Good Manufacturing Practice Audit By Israeli Ministry Of Health
Brief: Polypid Ltd Announces Successful Completion Of Manufacturing Process Validation For D-Plex(100)
PolyPid Ltd reports results for the quarter ended in June - Earnings Summary
Brief: PolyPid Ltd. Q2 EPS USD 0.13
PolyPid Ltd expected to post a loss of 31 cents a share - Earnings Preview
Brief: PolyPid Announces Recruitment Of First Patient In Revised Shield II Phase 3 Trial Evaluating D-Plex₁₀₀ For Prevention Of Abdominal Colorectal Surgical Site Infections
Brief: PolyPid Announces 180-Day Extension To Regain Compliance With Nasdaq Minimum Bid Requirement
PolyPid Ltd reports results for the quarter ended in March - Earnings Summary
Brief: Polypid Provides Corporate Update And Reports Q1 2023 Financial Results
PolyPid Ltd expected to post a loss of 26 cents a share - Earnings Preview
Brief: PolyPid Announces Receipt Of Nasdaq Notification Of Minimum Stockholders’ Equity Non-Compliance
Brief: PolyPid Announces Pricing Of $6.2 Mln Underwritten Public Offering Of Shares
Brief: Polypid Announces Proposed Underwritten Public Offering Of Ordinary Shares
PolyPid Ltd reports results for the quarter ended in December - Earnings Summary
Brief: Polypid Reports Fourth Quarter Financial Results
PolyPid Ltd expected to post a loss of 41 cents a share - Earnings Preview